Minocycline Treatment in SOD1 G93A Mice
Objective: To assess the therapeutic effects of minocycline treatment on disease progression in SOD1 G93A transgenic mice
This is a Minocycline Treatment in SOD1 G93A Mice protocol using mouse as the model organism. The procedure involves 4 procedural steps, 1 materials. Extracted from a 2013 paper published in Cell Death and Disease.
Model and subjects
mouse • B6.Cg-Tg [SOD1-G93A] 1Gur/J • unknown • 8 weeks at treatment start • not specified
Study window
~8 week study window
Core workflow
Animal acquisition and genotyping • Random group assignment • Minocycline administration initiation
Primary readouts
- Disease progression in SOD1 G93A transgenic mice
- Therapeutic effects of minocycline treatment
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Animal acquisition and genotyping
SOD1 G93A transgenic mice (B6.Cg-Tg [SOD1-G93A] 1Gur/J line) were purchased from Jackson Laboratory. Maintenance and genotyping protocols were performed according to previously described methods.
Note: Mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA)
View evidence from paper
“SOD1 G93A transgenic mice, which carry the G93A mutant form of the human SOD1 (B6.Cg-Tg [SOD1-G93A] 1Gur/J line), were purchased from the Jackson Laboratory”
Random group assignment
Transgenic mice were randomly divided into two groups: minocycline hydrochloride-treated group and untreated control group
Note: Randomization method not specified
View evidence from paper
“The transgenic mice were randomly divided into minocycline hydrochloride (Nichi-iko Pharmacceutical Co. Ltd., Toyama, Japan)-treated and untreated groups”
Minocycline administration initiation
Minocycline hydrochloride treatment was initiated at 8 weeks after birth
Note: Treatment continued until end stage of disease
View evidence from paper
“Minocycline (33 mg/kg) was administered intraperitoneally five times a week from 8 weeks after birth to end stage”
Intraperitoneal minocycline administration
Minocycline was administered via intraperitoneal injection at a dose of 33 mg/kg, five times per week
Note: Route of administration: intraperitoneal; Frequency: 5 times per week; Dose: 33 mg/kg
View evidence from paper
“Minocycline (33 mg/kg) was administered intraperitoneally five times a week from 8 weeks after birth to end stage”